Humedix Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
Humedix Stock Forecast and Price Target
Humedix's stock is projected to advance by 65.93% from the previous closing price if it reaches the average target of ₩56000.00 by the year's end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of ₩56000.00 and a low-end estimate of ₩56000.00. If you are not interested in A200670 stock, you may be interested in its competitors.
65.93% Upside
Humedix Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Humedix's Price has decreased by 100.00%, from ₩14.76k to ₩0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach ₩40.78k – an increase of 100.00%. The Humedix forecast is for Fair Value to reach ₩41.28k or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A207940 Stock Forecast | Samsung Biologics | Buy |
7
|
₩781.00k | Buy/Sell | ₩0.00B | 34.44% |
| A068270 Stock Forecast | Celltrion | Outperform |
16
|
₩189.00k | Buy/Sell | ₩215.28k | 21.69% |
| A091990 Stock Forecast | Celltrion Healthcare | - |
12
|
₩75.90k | Buy/Sell | ₩90.17k | -100.00% |
| A196170 Stock Forecast | ALTEOGEN | Outperform |
6
|
₩176.90k | Buy/Sell | ₩83.33k | -20.86% |
| A068760 Stock Forecast | Celltrion Pharm | - |
11
|
₩96.10k | Buy/Sell | ₩11.33k | -100.00% |
Humedix Revenue Forecast for 2023 - 2025 - 2030
In the last year, Humedix's Revenue has increased by 12.70%, going from ₩98.48B to ₩110.99B. In the next year, analysts are expecting an increase in Revenue, predicting it will reach ₩193.40B – an increase of 74.25%. The Humedix forecast is for Revenue to reach ₩186.01B or grow by 67.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A141080 Stock Forecast | LegoChem Biosciences | Outperform |
7
|
₩68.10k | Buy/Sell | ₩66.50k | 35.10% |
| A006280 Stock Forecast | GC Biopharma | Buy |
16
|
₩114.30k | Buy/Sell | ₩146.43k | 25.98% |
| A007390 Stock Forecast | NatureCell | - |
0
|
₩7.29k | Buy/Sell | ₩0.00 | -100.00% |
.jpg)
Humedix Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, Humedix's Dividend per Share has fallen from ₩400.00 to ₩400.00 – a 0.00% decrease. For next year, the 1 analysts predict Dividend per Share of ₩700.00, which would mean an increase of 75.00%. Over the next seven years, the pros' prediction is Dividend per Shareof ₩708.38, which would mean a seven-year growth forecast of 77.10%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A256840 Stock Forecast | BNC Korea | - |
0
|
₩3.56k | Buy/Sell | ₩0.00 | -100.00% |
| A298380 Stock Forecast | ABL Bio | Outperform |
6
|
₩26.00k | Buy/Sell | ₩37.00k | 42.31% |
| A214370 Stock Forecast | Caregen | - |
18
|
₩22.00k | Buy/Sell | ₩50.00k | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A115450 Stock Forecast | HLB Therapeutics | - |
6
|
₩11.23k | Buy/Sell | ₩20.77k | -100.00% |
| A214450 Stock Forecast | PharmaResearch | Outperform |
16
|
₩127.60k | Buy/Sell | ₩165.00k | 37.15% |
| A086900 Stock Forecast | Medy-Tox | Outperform |
8
|
₩135.00k | Buy/Sell | ₩335.00k | 174.07% |
Humedix EBITDA Forecast for 2023 - 2025 - 2030
In the last year, Humedix's EBITDA has grown, increasing from ₩27.16B to ₩28.26B – a growth of 4.06%. The next year looks promising for Humedix, with analysts predicting EBITDA of ₩67.00B – an increase of 137.05%. Over the next seven years, experts anticipate that Humedix's EBITDA will grow at a rate of 152.81%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A293780 Stock Forecast | AptaBio Therapeutics |
0
|
₩7.62k | Buy/Sell | ₩0.00 | -100.00% | |
| A182400 Stock Forecast | NKMAX CO. | - |
7
|
₩5.66k | Buy/Sell | ₩0.00 | -100.00% |
| A144510 Stock Forecast | GC Cell | - |
11
|
₩38.50k | Buy/Sell | ₩74.00k | -100.00% |
Humedix EBIT Forecast for 2023 - 2025 - 2030
In the last year, Humedix's EBIT has gone down from ₩16.64B to ₩15.99B – a 3.90% drop. For the next year, analysts are expecting EBIT to reach ₩58.80B – an increase of 267.73%. Over the next seven years, experts predict that EBIT will grow by 285.14%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A041960 Stock Forecast | Komipharm International | - |
6
|
₩4.39k | Buy/Sell | ₩0.00 | -100.00% |
| A065660 Stock Forecast | Anterogen.Co.,Ltd. | - |
7
|
₩14.01k | Buy/Sell | ₩0.00 | -100.00% |
| A290650 Stock Forecast | L&C Bio | - |
17
|
₩20.30k | Buy/Sell | ₩0.00 | -100.00% |
Humedix EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Humedix's EPS has decreased by 100.00%, from ₩1587.00 to ₩0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach ₩4385.00 – an increase of 100.00%. The Humedix forecast is for EPS to reach ₩4438.49 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A235980 Stock Forecast | MedPacto | - |
4
|
₩9.70k | Buy/Sell | ₩23.00k | -100.00% |
| A087010 Stock Forecast | Peptron | - |
6
|
₩29.00k | Buy/Sell | ₩35.00k | -100.00% |
| A031390 Stock Forecast | Green Cross Cell | - |
14
|
₩38.55k | Buy/Sell | ₩80.00k | -100.00% |
.jpg)